Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator

Bioorganic and Medicinal Chemistry Letters

Volumn 27, Issue 2, 2017, Pages 303-308

  Geldenhuys, Werner J ^a   Caporoso, Joel ^b   Leeper, Thomas C ^b   Lee, Yoon Kwang ^c   Lin, Li ^d   Darvesh, Altaf S ^d   Sadana, Prabodh ^d  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF AKRON   (United States)

^c Northeast Ohio Medical University   (United States)

^d NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Diabetes; High fat diet; Homology modeling; Hyperlipidemia; Lipoprotein lipase; Liver cirrhosis; Obesity

Indexed keywords

CHOLESTEROL; LEAD; LIPOPROTEIN LIPASE ACTIVATOR; TRIACYLGLYCEROL; BENZENEACETAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; LIPOPROTEIN LIPASE;

ANIMAL EXPERIMENT; ARTICLE; BODY FAT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; HYDROGEN BOND; IN VIVO STUDY; LIPID DIET; LIPID STORAGE; LIVER; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; MOLECULAR DOCKING; SYNTHESIS;

ANIMALS; BENZENEACETAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; LIPOPROTEIN LIPASE; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85006892897     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2016.11.053     Document Type: Article

References (13)

1. 1 Smith, S.C. Jr., Allen, J., Blair, S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006), 2363–2372.
2. 2 Brunzell, J.D., Davidson, M., Furberg, C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51 (2008), 1512–1524.
3. 3 Brewer, H.B. Jr., Increasing HDL Cholesterol Levels. N Engl J Med 350 (2004), 1491–1494.
4. 4 Brewer, H.B. Jr., Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 83 (1999), 3F–12F.
5. 5 Gianturco, S.H., Ramprasad, M.P., Song, R., Li, R., Brown, M.L., Bradley, W.A., Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler Thromb Vasc Biol 18 (1998), 968–976.
6. 6 Geldenhuys, W.J., Lin, L., Darvesh, A.S., Sadana, P., Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. Drug Discov Today, 2016.
7. 7 Brunzell, J., Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. Sriver, C., Baudet, A., Sly, W., Valle, D., (eds.) The Metabolic and Molecular Basis of Inherited Disease, Vol. 7, 1995, McGraw-Hill, 1913–1932.
8. 8 Rip, J., Nierman, M.C., Ross, C.J., et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 26 (2006), 1236–1245.
9. 9 Tsutsumi, K., Inoue, Y., Shima, A., Iwasaki, K., Kawamura, M., Murase, T., The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92 (1993), 411–417.
10. 10 Hara, T., Kusunoki, M., Tsutsumi, K., et al. A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging. Eur J Pharmacol 350 (1998), 75–79.
11. 11 Tsutsumi, K., Inoue, Y., Shima, A., Murase, T., Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44 (1995), 414–417.
12. 12 Chiba, T., Miura, S., Sawamura, F., et al. Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand white rabbits. Arterioscler Thromb Vasc Biol 17 (1997), 2601–2608.
13. 13 Geldenhuys, W.J., Aring, D., Sadana, P., A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4). Bioorg Med Chem Lett 24 (2014), 2163–2167.